<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02249598</url>
  </required_header>
  <id_info>
    <org_study_id>STH16097</org_study_id>
    <nct_id>NCT02249598</nct_id>
  </id_info>
  <brief_title>Competitive Carriage of Neisseria Spp(Lactamica 2)</brief_title>
  <acronym>Lactamica 2</acronym>
  <official_title>Competitive Carriage of Neisseria Spp.; Discovering New Methods of Inhibiting Carriage of Neisseria Meningitidis (Lactamica 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheffield Teaching Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the future it is likely that we will replace the current schedule of injected vaccines&#xD;
      with interventions that interrupt transmission of infections in more subtle ways. The agent&#xD;
      that causes meningococcal disease (Neisseria meningitidis) colonises the nasopharynx of&#xD;
      individuals. In most people, the bacterium is harmless and survives for months in the&#xD;
      nasopharynx, however in a minority of people the bacteria can cause invasive disease.&#xD;
&#xD;
      Simply reducing colonisation amongst target groups may protect them, and the rest of the&#xD;
      population as well. In a previous study we investigated cross protective antibodies, and&#xD;
      found incidentally that inoculating adult volunteers with Neisseria lactamica, a harmless&#xD;
      'cousin' of N. meningitidis, possibly prevents N. meningitidis carriage. If true this could&#xD;
      lead to novel mechanisms of reducing colonisation in targeted groups, possibly in the form of&#xD;
      a nasal medication. The proposed study large experimental challenge study funded by&#xD;
      Meningitis UK that will aim to establish if N. lactamica does or does not inhibit&#xD;
      colonisation by N. meningitidis. We will also determine whether N. lactamica displaces&#xD;
      existing N. meningitidis carriage, and whether there are individuals who are innately&#xD;
      resistant to any Neisseria carriage. The study will recruit 300 volunteers between the ages&#xD;
      of 1830yrs from the two universities in Sheffield. It will involve placing droplets of&#xD;
      N.lactamica bacteria into the nose of half our group of volunteers, and a harmless water like&#xD;
      solution into the nose of the other half of volunteers. We will carry out nose swabs at&#xD;
      intervals over a six month period to establish if the pattern of N.meningitidis carriage is&#xD;
      effected by N.lactamica colonisation. If the findings are positive we will perform future&#xD;
      mechanistic investigations. A62.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants found to have carriage of the bacterium Neisseria meningitidis at 6 sampling points (culture of throat swaps) following innoculation as baseline of subjects with the bacterium Neisseria lactamica</measure>
    <time_frame>number of positive results presenting between day 0 (baseline) until study completion (28 weeks)</time_frame>
    <description>culture of throat swabs at 2 weeks, 4 weeks, 8 weeks, 16 weeks, 26 weeks and 28 weeks.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Neisseria Lactamica</condition>
  <arm_group>
    <arm_group_label>Univeristy of Sheffield</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lactamica</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hallam University</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate Buffered Saline (PBS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lactamica</intervention_name>
    <arm_group_label>Univeristy of Sheffield</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Hallam University</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently healthy&#xD;
&#xD;
          -  Students and university employees from either Sheffield Hallam University or the&#xD;
             University of Sheffield between the ages of 18 and 25yrs.&#xD;
&#xD;
          -  Fully conversant in the English language&#xD;
&#xD;
          -  Able to attend the full protocol timetable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals who are Immunocompromised due to a medical condition&#xD;
&#xD;
          -  Individuals taking immune modifying medications (not including inhaled steroids)&#xD;
&#xD;
          -  Individuals in close contact with immunocompromised people including medical students&#xD;
             with full time clinical attachments.&#xD;
&#xD;
          -  Individuals who have an current infection&#xD;
&#xD;
          -  Current Smokers&#xD;
&#xD;
          -  People with an allergy to yeast extract.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Read</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheffield NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorskshire</state>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>August 12, 2014</study_first_submitted>
  <study_first_submitted_qc>September 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

